Ethris Reports Positive Phase 2a Data for ETH47 in Asthma Patients

Ethris reported 40-fold lower virus load versus placebo on Day 2, at peak viral replication, in topline Phase 2a data for nasal mRNA candidate ETH47 in asthma patients challenged with rhinovirus.